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Key points: 
Intravenous iron administered following hip fracture has a modest effect on erythropoiesis. 
The effect of intravenous iron on haemoglobin is too delayed to affect hospital-based 
outcomes such as transfusion rates and return to home. 
It is unlikely that intravenous iron will have a clinically significant benefit on longer-term 
outcomes.  
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Summary  
Background: Anaemia following hip fracture is common and associated with worse 
outcomes. Intravenous iron is a potential non-transfusion treatment for this anaemia and 
has been found to reduce transfusion rates in previous observational studies. There is good 
evidence for its use in elective surgical populations.  
Objective: to examine the impact of intravenous iron on erythropoiesis following hip 
fracture.  
Design: two-centre, assessor-blinded, randomised, controlled trial of patients with primary 
hip fracture and no contra-indications to intravenous iron.  
Method: The intervention group received three doses of 200mg iron sucrose over 30 
minutes (Venofer, Vifor Pharma, Bagshot Park, UK) on three separate days. Primary 
outcome was reticulocyte count at day 7 after randomisation. Secondary outcomes included 
haemoglobin concentration, complications and discharge destination. Eighty participants 
were randomised.  
Results: There was a statistically significantly greater absolute final reticulocyte count in the 
iron group (89.4 (78.9 - 101.3) x 109 cells.l-1 (n = 39) vs the control (72.2 (63.9 – 86.4)) x 109 
cells.l-1 (n = 41); p = 0.019; (mean (95% confidence intervals) of log transformed data).  
There were no differences in final haemoglobin concentration (99.9 (95.7 – 104.2) vs 102.0 
(98.7 - 105.3) p = 0.454) or transfusion requirements in the first week (11 (28%) vs 12 (29%); 
p = 0.899). Functional and safety outcomes were not different between the groups. 
Conclusions: Although intravenous iron does stimulate erythropoiesis following hip fracture 
in older people, the effect is too small and too late to affect transfusion rates. 
Trial Registry Numbers 
ISRCTN:76424792; EuDRACT: 2011-003233-34
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Optimal blood management for people admitted with hip fracture remains unclear. Around 
30% of people are mildly anaemic on admission and 10% moderately anaemic (haemoglobin 
concentration < 100 g.l-1) [1]. Given the potential harms associated with blood transfusion, 
lack of convincing benefit [2], and significant cost, alternative approaches to mitigate the 
deleterious effects of anaemia are needed [3]. 
Oral iron is known to be ineffective [4]. Observational studies have suggested that 
intravenous iron may be beneficial in elective orthopaedic surgery and in people with hip 
fracture [5-10].  
A single randomised-controlled trial of intravenous iron in hip fracture was inconclusive 
[11]. Before embarking on a larger trial, we therefore wished to answer the question: does 
early intravenous iron improve markers of erythropoiesis in a contemporary hip fracture 
population? 
Methods 
We conducted a prospective parallel group, randomised, controlled, assessor-blinded study 
across two English National Health Service (NHS) Hospitals. Details of regulatory approvals 
are given in Appendix 1 in the supplementary data on the journal website 
(www.academic.oup.com/ageing).  
Full details of the protocol have been published previously [12].  The only change of 
significance was the addition of a second site to enhance recruitment in 2015. 
Inclusion criteria were: ≥ 70 years old; emergency admission with primary fracture of the hip 
within previous 24 hours and able to gain written informed consent from the participant. 
Exclusions included severe infection on admission, liver disease, known sensitivity to 
intravenous iron, concomitant oral iron therapy, and taking clopidogrel. All participants gave 
written consent following receipt of written and verbal information.  
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Standard care 
Standard care was the same for all participants, aiming to meet national standards (see 
Appendix 2).  
Transfusion triggers 
Intra- and immediate postoperative transfusion was at the discretion of the anaesthetist. 
Postoperative transfusion guidance was, in order of clinical priority: 
• Ongoing blood loss with hypovolaemia; 
• Symptomatic anaemia: anaemia with haemoglobin concentration < 100 g.l-1 
associated with persistent hypotension, angina, heart failure or cerebral dysfunction; 
• Asymptomatic anaemia with haemoglobin concentration < 80 g.l-1; 
• Relative anaemia (haemoglobin concentration significantly less than normal for the 
patient) and poor functional recovery following surgery (in the view of the attending 
clinician) (This criterion was never used within the study). 
Study intervention 
Participants randomised to the intervention group received three doses of 200mg iron 
sucrose over 30 minutes (Venofer, Vifor Pharma, Bagshot Park, UK) on three separate 
occasions: 
Day 1 (within 24 hours of admission);  
Day 1 postoperative; or second morning following admission if not yet gone to theatre 
Day 2 postoperative; or third morning following admission if not yet gone to theatre 
Data collected 
Basic participant characteristics on admission included: age, sex, admission source, 
admission and day one haemoglobin concentration, type of fracture, operation performed, 
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time from admission to surgery, reticulocyte index (proportion (%) of red blood cells that 
are reticulocytes). Full blood count and reticulocyte counts were taken on days 1 to 7 post-
randomisation. Serum transferrin receptor concentrations were taken on days 1 and 7 post-
randomisation. The Cumulated Ambulation Score [13, 14] was recorded on the first three 
post-operative days. Infective and cardiovascular complications were reported using the 
Post-operative Morbidity Survey criteria [15]. 
Randomisation, blinding and statistical analysis are described in Appendix 3. The primary 
outcome was absolute reticulocyte count on day 7. Secondary outcomes are detailed in 
appendix 4. 
Funding and sources of support 
This work was supported by a grant from the Association of Anaesthetists. There was no 
funding, support or involvement in any aspect of the study from the manufacturers of 
intravenous iron. 
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Results 
Eighty patients were randomised, and primary outcome data were available for 73 
participants (CONSORT summary in Appendix 5 figure 1). 
All participants randomised to intravenous iron received at least one dose. Seven 
participants did not receive all three doses (3 only received one dose, 4 received two doses). 
The reasons for non-administration and incomplete primary data are detailed in Appendix 6.  
Participant characteristics are shown in table 1 and in Appendix 7 supplementary tables 1B-
F. 
Table 1 Characteristics of patients included in the study.  
There was a statistically significantly greater absolute final reticulocyte count in the iron 
group (89.4 (78.9 - 101.3) x 109 cells.l-1 (n = 35) vs the control (72.2 (63.9 – 86.4)) x 109 cells.l-
1 (n = 37); p = 0.019; (mean (95% confidence intervals).   
There were no statistically significant differences in final or maximum haemoglobin 
concentrations, nor in any measures of transfusion requirement. (Table 2 and Appendix 7, 
supplementary tables 2B-F). The changes in haematological indices over the first seven days 
are shown in Appendix 5 supplementary figures 2A-F. 
Table 2 Haematological outcome measures. 
There were no statistically significant differences between the groups in any other outcome 
measures. (Appendix 7, supplementary table 3). 
Adverse events are detailed in Appendix 8. 
Discussion 
Intravenous iron stimulated erythropoiesis in patients in the first week following hip 
fracture. This was not translated into differences in haemoglobin concentration nor a 
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reduction in transfusion requirements. Functional outcomes were unchanged and there was 
no evidence of increased risk of infection or cardiovascular complications.  
The participants were similar to previous studies of patients with hip fracture. The clinically 
relevant difference compared with the overall hip fracture population is that all participants 
had mental capacity, a lower risk group compared with those with dementia. The relatively 
low recruitment proportion might impact on the generalisability of the findings; regulatory 
approvals did not permit this drug study in people without capacity.  
The groups were well matched and time to theatre was consistent with contemporary 
practice in the UK. Of note, this study again demonstrates the large decrease (approximately 
27 g.l-1) in haemoglobin seen following hip fracture, with extracapsular fractures having the 
greatest decrease (see appendices 5 & 7). 
In contrast to previous observational studies, the increased reticulocyte production did not 
translate into greater haemoglobin concentrations nor reduced transfusion requirements. 
The early post-operative transfusion rate was around 27%, lower than in previous studies. 
Seven days may be too early to see an effect on haemoglobin concentration. However, late 
transfusion (between day 7 and discharge) was uncommon – 2 out of 80 participants. If the 
effect on haemoglobin concentration is delayed, and late transfusion is relatively 
uncommon then there is little scope for intravenous iron to reduce transfusion 
requirements. The interval between admission and surgery was short. The opportunity for 
the erythropoietic effect of iron to influence transfusion in the perioperative and early 
postoperative phase is therefore limited.  
At the trial development stage, iron sucrose, given as three divided doses, was chosen as 
the iron formulation. Five percent of participants declined to complete the three-day course 
of intravenous iron. Single dose formulations of ferric carboxymaltose are now available and 
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widely used. These might improve real-world effectiveness, requiring one administration, 
thereby ensuring a treatment dose is guaranteed. There are some data from long-term use 
with chronic kidney suggesting that greater erythropoietic efficacy is achieved with ferric 
carboxymaltose than with iron sucrose [16]. However, it is not clear whether this would 
translate into improved efficacy in the short-term context of post-hip fracture recovery. 
Although the role of tranexamic acid in hip fracture is still unresolved [17], it is an effective 
drug to reduce the need for early transfusion. There is an ongoing trial investigating the 
effect on transfusion rates of intravenous iron and / or tranexamic acid in hip fracture [18] 
but recruitment is not anticipated to finish until 2022. 
Study recruitment took much longer than anticipated for a variety of reasons including 
change in study personnel. The finding that almost 30% of potential participants lacked 
sufficient capacity for a drug trial is not particularly surprising. However, the high refusal 
rate of eligible participants severely hampered recruitment, a factor that is known to impact 
on clinical studies of older people [19].  
Our findings may have impact beyond the hip fracture population. First, we have 
demonstrated an erythropoietic effect of intravenous iron in older people following acute 
blood loss. This may have relevance to both in- and outpatient management of older people 
with blood loss not necessitating transfusion or resuscitation. Second, despite the admission 
low – normal haemoglobin, older people do demonstrate a reticulocyte response. With the 
caveat that this trial did not study the frailest of patients with hip fracture, older people can 
respond to acute production requirements, even in the presence of the suppressant effect 
of inflammation following injury and surgery. 
In conclusion, intravenous iron is an effective drug for stimulating erythropoiesis in older 
people following hip fracture. With changes in hip fracture management, particularly earlier 
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surgery and lower transfusion thresholds, it is unlikely to be an effective approach to 
reducing transfusion requirements. 
Acknowledgements are detailed in Appendix 6 
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Tables  
Table 1: Baseline characteristics of patients included in the study 
 Control (n = 41) Iron (n = 39) 
Age (years) 82.5 (5.8) 81.2 (7.0) 
Sex (male)    12 (29)     15 (39)  
Admission source          
 Home – Independent     36 (89)     36 (92)  
 Nursing care     0     1 (3)  
 Residential care     1 (2)      0 
 Warden controlled     4 (10)      2 (5)  
Operation          
 AO Screws     2 (5)      1 (3)  
 DHS    14 (34)      9 (23)  
 Hemiarthroplasty    18 (45)     22 (56)  
 Nail     2 (5)      4 (10)  
 Total Hip Arthroplasty     5 (12)      3 (8)  
Fracture type (%)         
 Extracapsular     17 (41)      13 (33)  
 Intracapsular    24 (59)     26 (67)  
Time to theatre (hours) 29.8 (20) 29.7 (17) 
Haemoglobin on admission  
 log  
 g.l-1 
 
4.83 (0.11) 
125.4 (121.4 - 129.6)  
  
4.81 (0.16) 
122.4 (116.5 - 128.6) 
Haemoglobin on admission < 120 g.l-1     15 (36.6)     16 (42.1)  
Reticulocyte count day 1 
 log 
 109 cell L-1 
  
3.70 (0.28) 
40.4 (36.9 - 44.2) 
  
3.74 (0.30) 
42.2 (38.3 - 46.6) 
Reticulocyte index day 1 
 log  
  % 
  
0.10 (0.32) 
1.11 (1.00 - 1.23) 
 
0.15 (0.36) 
1.16 (1.03 - 1.3) 
Haemoglobin day 1 
 log  
 g.l-1 
  
4.72 (0.18) 
112.7 (106.4 - 119.3) 
  
4.71 (0.20) 
111.1 (104.1 - 118.6) 
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Data are reported as mean (sd) or number (proportion). The mean (sd) for log transformed data are 
supplemented by the back-transformed mean (95% confidence interval). Day 1 is the day of consent 
and randomization, so haematological data are all before administration of iron. 
AO screws – parallel screw fixation; DHS – dynamic hip screw. 
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Table 2: Haematological outcomes 
 
Outcome Control (n = 41) Iron (n = 39) p 
Reticulocytes final day 
 log 
 109 cells.l-1 
(n = 37) 
4.28 (0.38) 
72.2 (63.9 - 86.4) 
(n = 35) 
4.49 (0.38) 
89.4 (78.9 - 101.3) 
 
0.019 
Reticulocytes day 7 
 log 
 109 cells.l-1 
(n = 30) 
4.33 (0.36) 
75.8 (66.5 - 86.4) 
(n = 29) 
4.51 (0.37) 
91.2 (79.8 - 104.2) 
 
0.056 
Reticulocyte index final day 
 log 
  % 
(n = 37) 
0.77 (0.42) 
2.19 (1.91 - 2.51) 
(n = 35) 
0.99 (0.35) 
2.69 (2.39 - 3.03) 
  
0.022 
Reticulocyte index day 7 
 log 
 % 
(n = 30) 
0.82 (0.42) 
2.28 (1.97 - 2.64) 
(n = 29) 
1.00 (0.33) 
2.73 (2.42 - 3.08) 
 
0.069 
Haemoglobin final day 
 log 
 g.l-1 
(n = 38) 
4.60 (0.14) 
99.9 (95.7 – 104.2) 
(n = 36) 
4.62 (0.10) 
102.0 (98.7 - 105.3) 
 
0.454 
Haemoglobin day 7 
 log 
 g.l-1 
(n = 33) 
4.61 (0.14) 
100.9 (96.4 - 105.6) 
(n = 29) 
4.64 (0.09) 
103.2 (99.7 - 106.8) 
 
0.466 
Minimum haemoglobin first 7 days 
 log 
 g.l-1 
 
4.51 (0.16) 
90.6 (86.1 - 95.2) 
 
4.52 (0.14) 
92.1 (88.0 - 96.2) 
 
0.638 
Maximum fall in haemoglobin first 7 days 
 log 
 g.l-1 
 
3.39 (0.69) 
29.5 (23.9 - 36.5) 
 
3.23 (0.74) 
25.3 (20.0 - 32.1) 
 
0.344 
Maximum reticulocytes first 7 days 
 log 
 109 cells.l-1 
 
4.29 (0.34) 
72.7 (66.5 – 80.6) 
 
4.49 (0.36) 
88.8 (79.3 - 99.4) 
 
0.022 
Maximum reticulocyte index first 7 days 
 log 
 % 
 
0.78 (0.40) 
2.17 (1.92 - 2.46) 
 
0.97 (0.36) 
2.63 (2.35 - 2.94) 
 
0.022 
Serum Transferrin Receptor Concentration 
final day (mg.l-1) 
(n = 29) 
17.4 (14.5 - 19) 
[10.1 - 24.8] 
(n= 26) 
16.1 (14.1 - 17.9) 
[9.3 - 24.8] 
0.418 
Total transfusions during admission 0 (0 - 1) [0 - 4] 0 (0 - 1) [0 - 4] 0.927 
Participants transfused during admission    12 (29)      11 (28)   1.000 
Total transfusions in first week 0 (0 - 1) [0 - 4] 0 (0 - 1) [0 - 4] 0.899 
Participants transfused during first week    11 (27)      11 (28)   1.000 
 
Data are reported as mean (sd), median (interquartile range) [range], or number 
(proportion). The mean (sd) for log transformed data are supplemented by the back-
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transformed mean (95% confidence interval). P values are two-side tests on the log-
transformed data, chi-squared tests on proportions and Mann-Whitney-U tests on non-
parametric data as appropriate. In cases of missing outcome data, the group totals are 
shown; all other outcomes were for all participants. 
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Appendix 1 
Regulatory information: 
Study recruitment commenced in 18th July 2012 and ended on 22nd July 2017. Relevant 
approvals were obtained: Nottingham Research Ethics Committee on 23 November 2011 
(reference number 11/EM/0310); the Nottingham University Hospitals Research and 
Development department on 2 August 2011 (reference number 68213), Birmingham 
Heartlands Research and Development department on 16 April 2014; and the UK Medicines 
and Healthcare products Regulatory Authority on 19 January 2012, (EuDRACT: 2011-003233-
34). The study was also registered with the National Institute for Health Research Portfolio 
and ISRCTN:76424792 (10 September 2012). The study complied with Good Clinical Practice 
standards set forth in the Declaration of Helsinki of 1975. 
Appendix 2 
Standard care 
Standard care was the same for all participants, aiming to meet national standards as set 
out by the National Institute of Clinical Excellence (CG124) [1]; Best Practice Tariff [2, 3], 
British Orthopaedic Society Standard for Trauma [4], and Association of Anaesthetists [5]. 
This included fast-track admission for most patients, an integrated hip fracture pathway, 
surgery within 36 hours on a dedicated orthopaedic trauma list with senior surgeons and 
anaesthetists, and shared care with consultant ortho-geriatricians. Surgical and anaesthetic 
treatment options were at the discretion of the surgeons and anaesthetists and were not 
affected by the study. 
Tranexamic acid was not routinely used during the period of the study. Wound drains were 
not routinely used, nor were pressure dressings. Autologous transfusion was not used. 
Appendix 3 
Randomisation and blinding 
Participants were randomised on a one-to-one basis to standard care or intravenous iron. 
Randomisation was performed using a password-controlled, web-based randomisation 
service (Nottingham Clinical Trials Unit) with random block sizes and the sequence was kept 
blinded until data-lock. 
Participants were not blinded to allocation (intravenous iron is an unmistakeable bright 
orange). Blood tests were ordered, and results obtained, without any reference to group 
allocation. Mobility assessments and discharge arrangements were performed by 
physiotherapists and clinical staff uninvolved with the study. 
Statistical approaches 
All calculations were performed using R statistical package [6]. Descriptive statistics were 
used for demographic data. 
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Log transformation was used to enable parametric testing as appropriate; means and 
confidence intervals are back transformed to the natural units. In cases of missing 
haematological data at day 7, last value (day 6) was carried forward (referred to as ‘final 
day’). Missing Cumulated Ambulation Scores were imputed as last value carried forward. 
Power analysis was performed based on previous studies of intravenous iron in hip fracture. 
Garcia-Erce [7] demonstrated an absolute difference in reticulocyte index of 1.75% with 
standard deviation of 1.6%. A study of 70 participants would provide 80% power for 
detecting a difference of 1.0%. This equates to a relative difference in absolute reticulocyte 
count of 40 x 109 cell.l-1. An extra 10 participants were planned to allow for drop-outs. The 
study was not powered for secondary outcomes. 
Appendix 4 
Secondary outcomes 
Secondary haematological outcomes were: 
Absolute reticulocyte count, reticulocyte index (proportion of red cells that are 
reticulocytes), and haemoglobin concentration daily in the first seven days after 
randomisation. 
Serum transferrin receptor concentrations at day 7. 
Transfusion requirements. Number of participants transfused, and units transfused per 
participants: during admission, in first seven days, in first 7 days excluding pre- and intra-
operative transfusion. 
Functional and safety outcomes included proportions of participants with infective and 
cardiovascular complications, length of hospital stay, and thirty-day mortality. 
Appendix 5 
Figures – see separate file 
Appendix 6 
Non-administration and incomplete data 
The reasons for non-administration of intravenous iron doses were: patient refusal (itching, 
stinging at cannula site, blurred vision, no reason recorded); pyrexia > 38.5℃ (2 participants) 
and systemic illness. 
Three participants were discharged before final reticulocyte counts were collected, two 
were not taken for unknown reasons, one patient’s ward was closed to non-essential 
(research) staff and one participant declined to have blood samples taken but consented to 
follow-up and use of data. 
Appendix 7 
Tables – see separate file 
20 
 
Appendix 8 
Adverse events 
Ten serious adverse events were reported. Three deaths in the intravenous iron group were 
reviewed by an independent senior academic outside of the study team’s department who 
felt none of the deaths were attributable to the study or directly related to intravenous iron. 
One episode of cardiac arrhythmia and two episodes of hospital acquired pneumonia were 
attributed as possibly related to intravenous iron; all three resolved. 
Appendix 9 
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Appendix 7: Supplementary Tables  
BASELINE CHARACTERISTICS 
 
Table 1B  
Characteristics of transfused participants 
 
 Control (n = 11) Iron (n = 11) 
Age (years) 82.9 (4.66) 83.2 (8.22) 
Sex (Male)     4 (36.4)      4 (36.4)  
Admission source          
    Home - Independent    10 (91)      9 (82)  
    Nursing care     0 (0.0)      1 (9)  
    Residential care     1 (9)      0 (0)  
    Warden controlled     0 (0)      1 (9)  
Operation (%)          
 AO Screws 0 0 
    DHS     7 (64)      2 (18)  
   Hemiarthroplasty     3 (27)      5 (46)  
    Nail     1 (9)      2 (18)  
    Total hip arthroplasty     0 (0)      2 (18)  
Fracture type (%)          
    Extracapsular     9 (82)      4 (36)  
    Intracapsular     2 (18)      7 (64)  
Time to theatre (hours) 28.3 (17.2) 34.0 (24.2) 
Haemoglobin on admission  
 log  
 g.l-1 
 
 4.79 (0.16) 
120.4 (109.7 - 132.2) 
 
 4.68 (0.14) 
108.3 (99.7 - 117.7) 
Haemoglobin on admission < 120 g.l-1      6 (54.5)      8 (72.7)  
Reticulocyte count day 1 
 log 
 109 cell.l-1 
 
 3.70 (0.22) 
40.4 (35.4 - 46.3) 
 
 3.68 (0.34) 
39.7 (32.0 - 49.1) 
Reticulocyte index day 1 
 log  
  % 
 
 0.26 (0.35) 
1.29 (1.03 - 1.62) 
 
 0.27 (0.44) 
1.32 (1.00 - 1.73) 
Haemoglobin day 1 
 log  
 g.l-1 
 
 4.61 (0.21) 
100.5 (88.0 - 114.7) 
 
 4.55 (0.23) 
94.3 (82.5 - 107.92) 
23 
 
Data are reported as mean (sd) or number (proportion). The mean (sd) for log transformed data are 
supplemented by the back-transformed mean (95% confidence interval). Day 1 is the day of consent and 
randomization, so haematological data are all before administration of iron. 
AO screws – parallel screw fixation; DHS – dynamic hip screw. 
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Table 1C 
 
Characteristics of non-transfused participants 
 
 Control (n = 30) Iron (n = 28) 
Age (years) 82.4 (6.3) 80.4 (6.4) 
Sex (Male)     8 (26.7)     11 (39.3)  
Admission source   
    Home - Independent    26 (87)     27 (96)  
    Nursing care 0 0 
    Residential care 0 0 
    Warden controlled     4 (13)      1 (4)  
Operation (%)   
 AO Screws     2 (7)      1 (4)  
    DHS     7 (23)      7 (25)  
   Hemiarthroplasty    15 (50)     17 (61)  
    Nail     1 (3)      2 (7)  
    THR     5 (17)      1 (4)  
Fracture type (%)   
    Extracapsular     8 (27)      2 (32)  
    Intracapsular    22 (73)     19 (68)  
Time to theatre (hours) 30.4 (21.5) 28.1 (14) 
Haemoglobin on admission  
 log  
 g.l-1 
  
4.85 (0.08) 
127.3 (123.7 - 131.0) 
  
4.86 (0.14) 
128.4 (122.1 - 135.1) 
Haemoglobin on admission < 120 g.l-1      9 (30)      8 (29)  
Reticulocyte count day 1 
 log 
 109 cell.l-1 
  
3.70 (0.31) 
40.3 (36.0 - 45.2) 
  
3.77 (0.29) 
43.3 (38.7 - 48.3) 
Reticulocyte index day 1 
 log  
  % 
  
0.05 (0.29) 
1.05 (0.94 - 1.17) 
  
0.09 (0.31) 
1.1 (0.97 - 1.24) 
Haemoglobin day 1 
 log  
 g.l-1 
  
4.77 (0.14) 
117.6 (111.4 - 124.1) 
  
4.78 (0.15) 
119.1 (112.6 – 126.0) 
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Table 1D 
 
Characteristics of participants admitted with haemoglobin < 120 g.l-1 
 
 Control (n= 15) Iron (n = 16) 
Age (years) 83.9 (5.1) 80.9 (7.9) 
Sex (Male)     3 (20)      4 (25)  
Admission source         
    Home - Independent    12 (80)    15 (94) 
    Nursing care 0 0 
    Residential care     1 (7)     0 
    Warden controlled     2 (13)     1 (6)  
Operation (%)         
 AO Screws     0      1 (6) 
    DHS     7 (47)     3 (19) 
   Hemiarthroplasty     5 (33)     8 (50) 
    Nail     1 (7)     3 (19) 
    THR     2 (13)     1 (6) 
Fracture type (%)         
    Extracapsular     8 (53)      6 (37) 
    Intracapsular     7 (47)     10 (63) 
Time to theatre (hours) 32.2 (27) 24.7 (12 
Haemoglobin on admission  
 log  
 g.l-1 
  
4.73 (0.07) 
113.7 (109.5 - 118.1) 
 
4.65 (0.09) 
104.4 (99.7 - 109.4) 
Haemoglobin on admission < 120 g.l-1     15 (100.0)     16 (100.0)  
Reticulocyte count day 1 
 log 
 109 cell.l-1 
  
3.65 (0.29) 
38.3 (32.9 - 44.5) 
  
3.60 (0.33) 
36.7 (30.9 - 43.7) 
Reticulocyte index day 1 
 log  
 % 
  
0.18 (0.36) 
1.19 (0.98 - 1.45) 
  
0.14 (0.44) 
1.15 (0.92 - 1.45) 
Haemoglobin day 1 
 log  
 g.l-1 
 
4.61 (0.19) 
100.3 (90.9 - 110.6) 
 
4.57 (0.18) 
96.1 (88.2 - 104.8) 
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Table 1E 
 
Characteristics of participants with intracapsular fractures 
 
 Control (n = 24) Iron (n = 26) 
Age (years) 82.0 (6.4) 80.4 (6.5) 
Sex (Male)     6 (25)    11 (42)  
Admission source             
    Home - Independent    20 (83)    24 (92)  
    Nursing care 0 0 
    Residential care 0 0 
    Warden controlled     4 (17)      2 (8)  
Operation (%)         
   AO Screws     2 (8)      1 (4)  
   DHS 0  0  
   Hemiarthroplasty    17 (71)     22 (85)  
   Nail     0      0   
   Total hip arthroplasty     5 (21)      3 (12)  
Time to theatre (hours) 30.0 (17) 31.9 (18.2) 
Haemoglobin on admission  
 log  
 g.l-1 
  
4.85 (0.08) 
127.3 (123.2 - 131.5) 
  
4.82 (0.16) 
123.6 (116.3 - 131.4) 
Haemoglobin on admission < 120 g.l-1      7 (29)     10 (39)  
Reticulocyte count day 1 
 log 
 109 cell.l-1 
  
3.70 (0.30) 
40.4 (35.5 - 45.9) 
  
3.70 (0.29) 
40.6 (36.1 - 45.6) 
Reticulocyte index day 1 
 log  
 % 
  
0.02 (0.29) 
1.02 (0.89 - 1.16) 
  
0.08 (0.32) 
1.08 (0.94 - 1.24) 
Haemoglobin day 1 
 log  
 g.l-1 
  
4.78 (0.15) 
119.4 (112.0 - 127.2) 
  
4.75 (0.19) 
115.5 (107.2 - 124.4) 
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Table 1F 
 
Characteristics of participants with extracapsular fractures 
 
 Control (n = 17) Iron (n = 13) 
Age (years) 83.4 (5.1) 82.6 (7.9) 
Sex (Male)     6 (35)     4 (31) 
Admission source   
    Home - Independent     16 (94)     12 (92) 
    Nursing care     0     1 (8) 
    Residential care 1 (6) 0 
    Warden controlled 0 0 
Operation (%)            
   AO Screws 0          0  
   DHS     14 (82)     6 (69) 
   Hemiarthroplasty 1 (6) 0 
   Nail 2 (12) 4 (31) 
   THR 0 0 
Time to theatre (hours) 29.5 (24.4) 25.5 (15.0) 
Haemoglobin on admission  
 log  
 g.l-1 
  
4.81 (0.14) 
122.9 (115.2 - 131.1) 
  
4.79 (0.16) 
120 (110.1 - 130.7) 
Haemoglobin on admission < 120 g.l-1  8 (47) 6 (46) 
Reticulocyte count day 1 
 log 
 109 cell.l-1 
  
3.70 (0.27) 
40.4 (35.6 - 45.8) 
  
3.82 (0.32) 
45.7 (38.1 - 54.8) 
Reticulocyte index day 1 
 log  
 % 
 
 0.21 (0.32) 
1.24 (1.05 – 1.46) 
  
0.27 (0.40) 
1.31 (1.04 – 1.64) 
Haemoglobin day 1 
 log  
 g.l-1 
  
4.64 (0.18) 
103.5 (94.4 – 113.5) 
  
4.64 (0.22) 
103.5 (91.8 – 116.6) 
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OUTCOMES 
 
Table 2B 
Haematological outcomes for participants transfused in the first seven days 
 
 Control (n = 11) Iron (n = 11) p 
Reticulocytes final day 
 log 
 109 cells.l-1 
  
4.39 (0.38) 
80.4 (64.3 - 100.6) 
   
4.35 (0.44) 
77.8 (59.8 - 101.2) 
  
0.852 
Reticulocytes day 7 
 log 
 109 cells.l-1 
(n = 8) 
4.42 (0.42) 
82.8 (61.7 – 111.1) 
(n = 9) 
4.41 (0.44) 
82.1 (61.7 - 109.1) 
 
0.967 
Reticulocyte index final day 
 log 
  % 
 
0.95 (0.43) 
2.58 (2.01 - 3.33) 
   
0.86 (0.39) 
2.36 (1.88 - 2.97) 
  
0.614 
Reticulocyte index day 7 
 log 
 % 
 
1.01 (0.46) 
2.76 (2.01 - 3.79) 
 
0.93 (0.36) 
2.54 (2.01 - 3.2) 
 
0.677 
Haemoglobin final day 
 log 
 g.l-1 
  
4.55 (0.10) 
94.7 (89.4 - 100.3) 
   
4.62 (0.08) 
101.3 (96.4 - 106.5) 
  
0.097 
Haemoglobin day 7 
 log 
 g.l-1 
(n = 9) 
4.53 (0.09) 
93.0 (87.9 - 98.4) 
(n = 9) 
4.62 (0.09) 
101.4 (95.3 - 107.8) 
 
0.061 
Minimum haemoglobin first 7 days 
 log 
 g.l-1 
  
4.38 (0.20) 
79.9 (70.8 - 90.1) 
   
4.39 (0.12) 
80.6 (74.9 - 86.7) 
  
0.895 
Maximum fall in haemoglobin first 7 days 
 log 
 g.l-1 
  
3.35 (1.20) 
28.5 (14.0 - 57.9) 
   
3.00 (1.04) 
20.0 (10.8 - 36.9) 
  
0.466 
Maximum reticulocytes first 7 days 
 log 
 109 cells.l-1 
  
4.40 (0.38) 
81.2 (65.0 - 101.4) 
   
4.43 (0.41) 
84.1 (66.2 - 106.9) 
  
0.835 
Maximum reticulocyte index first 7 days 
 log 
 % 
  
0.95 (0.43) 
2.59 (2.01 - 3.34) 
   
0.93 (0.35) 
2.54 (2.06 - 3.13) 
  
0.835 
STRC final day 17.4 (14.5 - 18.2)  
[10.1 - 23.1] 
15.5 (12.1 - 18.2)  
[9.3 - 21] 
0.607 
Total transfusions during admission 2 (2 - 2.5) [1 - 4] 2 (2 - 2.5) [1 - 4] 1.000 
Total transfusions in first week 2 (2 - 2) [1 - 4] 2 (2 - 2.5) [1 - 4] 0.882 
 
Data are reported as mean (sd), median (interquartile range) [range], or number (proportion). The mean (sd) for 
log transformed data are supplemented by the back-transformed mean (95% confidence interval). P values are 
from: two-side tests on the log-transformed data; chi-squared tests with continuity correction; and Mann-
Whitney-U tests on non-parametric data. 
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Table 2C 
 
Haematological outcomes for non-transfused participants 
 
 Control (n = 30) Iron (n = 28) p 
Reticulocytes final day 
 log 
 109 cells.l-1 
(n = 26)   
4.23 (0.38) 
68.9 (59.6 – 79.6) 
(n = 24) 
4.56 (0.33) 
95.3 (83.3 - 108.9) 
  
0.002 
Reticulocytes day 7 
 log 
 109 cells.l-1 
(n = 22) 
4.31 (0.34) 
74.2 (64.4 - 85.3) 
(n = 20) 
4.56 (0.33) 
95.7 (82.7 - 110.7) 
 
0.015 
Reticulocyte index final day 
 log 
  % 
(n = 26)  
0.75 (0.40) 
2.01 (1.72 - 2.35) 
 (n = 24)  
1.05 (0.33) 
2.86 (2.5 - 3.26) 
  
0.002 
Reticulocyte index day 7 
 log 
 % 
(n = 22) 
0.76 (0.39) 
2.13 (1.82 - 2.5) 
(n = 20) 
1.04 (0.32) 
2.82 (2.45 - 3.24) 
 
0.015 
Haemoglobin final day 
 log 
 g.l-1 
(n = 27)   
4.62 (0.14) 
102.0 (96.7 - 107.5) 
  (n = 25) 
4.63 (0.11) 
102.2 (98.1 - 106.6) 
  
0.871 
Haemoglobin day 7 
 log 
 g.l-1 
(n = 24) 
4.64 (0.14) 
103.9 (98.4 - 109.8) 
(n = 20) 
4.64 (0.10) 
104.0 (99.7 - 108.5) 
 
0.988 
Minimum haemoglobin first 7 days 
 log 
 g.l-1 
   
4.55 (0.12) 
94.9 (90.9 - 99.0) 
   
4.57 (0.11) 
97.0 (93.0 - 101.2) 
  
0.475 
Maximum fall in haemoglobin first 7 days 
 log 
 g.l-1 
   
3.40 (0.41) 
30.0 (25.9 - 34.7) 
   
3.33 (0.58) 
27.9 (22.4 - 34.7) 
  
0.676 
Maximum reticulocytes first 7 days 
 log 
 109 cells.l-1 
   
4.25 (0.32) 
69.8 (62.2 – 78.2) 
   
4.51 (0.35) 
90.7 (79.8 - 103.2) 
  
0.004 
Maximum reticulocyte index first 7 days 
 log 
 % 
   
0.70 (0.38) 
2.01 (1.76 - 2.30) 
   
0.98 (0.37) 
2.66 (2.32 - 3.05) 
  
0.006 
STRC final day 17.5 (14.8 - 19.2)  
[11.4 - 24.8] 
16.1 (14.9 - 17.6)  
[9.6 - 24.8] 
0.522 
Total transfusions during admission     0 (0 - 0) [0 - 2]     0 (0 - 0) [0 - 0] 1.000 
Participants transfused during admission      1 (3)       0  1.000 
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Table 2D 
 
Haematological outcomes for participants admitted with haemoglobin < 120 g.l-1 
 
 Control (n = 15) Iron (n = 16) p 
Reticulocytes final day 
 log 
 109 cells.l-1 
  
4.12 (0.40) 
61.3 (49.7 - 75.6) 
(n = 15)  
4.31 (0.34) 
74.8 (62.9 – 89.0) 
  
0.160 
Reticulocytes day 7 
 log 
 109 cells.l-1 
(n = 10) 
4.16 (0.34) 
64.2 (52.4 - 78.7) 
(n = 11) 
4.28 (0.27) 
72.2 (61.4 - 84.8) 
  
0.387 
Reticulocyte index final day 
 log 
  % 
  
0.68 (0.46) 
1.96 (1.55 - 2.50) 
 (n = 15) 
0.85 (0.34) 
2.33 (1.96 - 2.78) 
  
0.259 
Reticulocyte index day 7 
 log 
 % 
(n = 10) 
0.76 (0.43) 
2.13 (1.64 - 2.78) 
(n = 11) 
0.81 (0.23) 
2.25 (1.96 - 2.58) 
 
0.717 
Haemoglobin final day 
 log 
 g.l-1 
 
4.54 (0.11) 
93.4 (88.0 - 99.1) 
(n = 15) 
4.58 (0.09) 
97.9 (93.7 - 102.2) 
  
0.212 
Haemoglobin day 7 
 log 
 g.l-1 
(n = 12) 
4.53 (0.11) 
92.3 (86.9 - 98.1) 
(n = 11) 
4.60 (0.07) 
100.0 (95.9 - 104.2) 
  
0.050 
Minimum haemoglobin first 7 days 
 log 
 g.l-1 
  
4.45 (0.16) 
85.5 (78.9 - 92.8) 
  
4.43 (0.11) 
83.9 (79.4 - 88.6) 
  
0.688 
Maximum fall in haemoglobin first 7 days 
 log 
 g.l-1 
  
3.13 (0.90) 
22.8 (14.5 - 36.1) 
  
2.74 (0.88) 
15.5 (10.1 - 23.9) 
  
0.240 
Maximum reticulocytes first 7 days 
 log 
 109 cells.l-1 
  
4.15 (0.32) 
63.7 (54.1 - 74.9) 
  
4.38 (0.31) 
80.1 (68.7 - 93.4) 
  
0.053 
Maximum reticulocyte index first 7 days 
 log 
 % 
  
0.67 (0.43) 
1.96 (1.58 - 2.44) 
  
0.90 (0.31) 
2.45 (2.1 - 2.86) 
  
0.109 
STRC final day 15.8 (14.3 - 17.9)  
[10.1 - 23] 
15.4 (14 - 18.2)  
[11.4 - 24.8] 
1.000 
Total transfusions during admission 0 (0 - 2) [0 - 4]     0.5 (0 - 2) [0 - 4] 1.000 
Participants transfused during admission     7 (47)     8 (50) 1.000 
Total transfusion during first 7 days 0 (0 - 2) [0 - 4] 0.5 (0 - 2) [0 - 4] 0.710 
Participants transfused during first 7 days     6 (40)     8 (50) 0.843 
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Table 2E 
 
Haematological outcomes for participants with intracapsular fractures 
 
 
 Control (n= 24) Iron (n = 26) p 
Reticulocytes final day 
 log 
 109 cells.l-1 
(n = 20)  
4.17 (0.34) 
64.4 (55.5 – 74.7) 
  (n = 23) 
4.36 (0.31) 
78.4 (69.1 – 88.9) 
  
0.053 
Reticulocytes day 7 
 log 
 109 cells.l-1 
(n = 16) 
4.24 (0.30) 
69.1 (59.7 – 80.0) 
(n = 20) 
4.41 (0.28) 
81.9 (72.4 - 92.8) 
 
0.090 
Reticulocyte index final day 
 log 
  % 
(n = 20)  
0.60 (0.35) 
1.82 (1.56 - 2.13) 
 (n = 23)  
0.87 (0.28) 
2.38 (2.13 - 2.67) 
  
0.008 
Reticulocyte index day 7 
 log 
 % 
(n = 16) 
0.65 (0.33) 
1.91 (1.62 - 2.25) 
(n = 20) 
0.91 (0.25) 
2.47 (2.22 - 2.76) 
  
0.012 
Haemoglobin final day 
 log 
 g.l-1 
  (n = 21) 
4.65 (0.13) 
105 (99.4 - 111) 
 (n = 23)  
4.63 (0.10) 
102.6 (98.3 - 107.1) 
 
0.506 
Haemoglobin day 7 
 log 
 g.l-1 
(n = 18) 
4.68 (0.11) 
108.2 (102.8 - 113.9) 
(n = 20) 
4.64 (0.10) 
103.7 (99.1 - 108.5) 
  
0.224 
Minimum haemoglobin first 7 days 
 log 
 g.l-1 
   
4.59 (0.12) 
98.1 (93.6 - 102.7) 
   
4.56 (0.14) 
95.3 (90.3 - 100.5) 
  
0.432 
Maximum fall in haemoglobin first 7 days 
 log 
 g.l-1 
   
3.29 (0.42) 
26.8 (22.7 - 31.7) 
   
3.23 (0.60) 
25.2 (20.1 - 31.7) 
 
0.678 
Maximum reticulocytes first 7 days 
 log 
 109 cells.l-1 
   
4.17 (0.31) 
64.6 (57.1 – 73.0) 
   
4.37 (0.29)) 
79.3 (70.9 - 88.7) 
 
0.019 
Maximum reticulocyte index first 7 days 
 log 
 % 
   
0.59 (0.34) 
1.80 (1.57 - 2.06) 
   
0.85 (0.29)) 
2.34 (2.09 - 2.62) 
 
0.005 
STRC final day 16.5 (13.9 - 18.4)  
[11.4 - 23.1] 
16 (14.1 - 16.4)  
[9.6 - 21] 
0.415 
Total transfusions during admission 0 (0 - 0) [0 - 2] 0 (0 - 0.8) [0 - 4] 0.173 
Participants transfused during admission      3 (12.5)       7 (26.9)   0.358 
Total transfusions in first week 0 (0 - 0) [0 - 1] 0 (0 - 0.8) [0 - 4] 0.050 
Participants transfused during first week      1 (4)      4 (15)  0.396 
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Table 2F 
 
Haematological outcomes for participants with extracapsular fractures 
 
 Control (n = 17) Iron (n = 13) p 
Reticulocytes final day 
 log 
 109 cells.l-1 
  
4.41 (0.39) 
82.5 (68.6 - 99.2) 
   
4.74 (0.38) 
115 (92.6 - 142.8) 
 0.031 
Reticulocytes day 7 
 log 
 109 cells.l-1 
(n = 14) 
4.43 (0.42) 
84.2 (67.7 - 104.6) 
(n = 9) 
4.75 (0.43) 
115.8 (87.4 - 153.5) 
0.090  
Reticulocyte index final day 
 log 
  % 
 
0.98 (0.42) 
2.66 (2.19 - 3.24) 
   
1.22 (0.37) 
3.4 (2.75 - 4.2) 
 0.117 
Reticulocyte index day 7 
 log 
 % 
(n = 14) 
1.02 (0.43) 
2.78 (2.22 - 3.48) 
(n = 9) 
1.22 (0.39) 
3.4 (2.63 - 4.38) 
0.269 
Haemoglobin final day 
 log 
 g.l-1 
 
4.54 (0.11) 
93.5 (88.6 - 98.7) 
 
4.61 (0.09) 
100.8 (95.8 - 106.1) 
 0.062 
Haemoglobin day 7 
 log 
 g.l-1 
(n = 15) 
4.53 (0.11) 
92.4 (87.4 - 97.6) 
(n = 9) 
4.63 (0.07) 
102.1 (97.2 - 107.2) 
0.024 
Minimum haemoglobin first 7 days 
 log 
 g.l-1 
  
4.39 (0.16) 
81.0 (75.1 - 87.3) 
   
4.45 (0.13) 
85.9 (80.2 - 92.1) 
 0.274 
Maximum fall in haemoglobin first 7 days 
 log 
 g.l-1 
  
3.52 (0.96) 
33.8 (21.4 - 53.4) 
   
3.28 (0.99) 
26.6 (15.5 - 45.5) 
 0.506 
Maximum reticulocytes first 7 days 
 log 
 109 cells.l-1 
  
4.45 (0.32) 
85.8 (73.9 - 99.7) 
   
4.71 (0.39) 
111.4 (90 - 137.9) 
 0.053 
Maximum reticulocyte index first 7 days 
 log 
 % 
  
1.02 (0.35) 
2.79 (2.36 - 3.28) 
   
1.20 (0.38) 
3.32 (2.71 - 4.07) 
 0.195 
STRC final day (n = 13) 
17.7 (15.8 - 19) [10.1 - 
24.8] 
(n = 6) 
19.2 (13.6 - 23.2) [9.3 - 
24.8] 
0.726 
Total transfusions during admission 2 (0 - 2) [0 - 4] 0 (0 - 2) [0 - 4] 0.314 
Participants transfused during admission     9 (53)      4 (31)   0.399  
Total transfusions in first week 2 (0 - 2) [0 - 4] 0 (0 - 2) [0 - 4] 0.293 
Participants transfused during first week     9 (53)      4 (31)   0.399  
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FUNCTIONAL AND SAFETY OUTCOMES 
Table 3:  
Secondary safety outcomes 
 
 Control (n = 41) Iron (n = 39) p 
Infective complications    12 (29)      8 (21)   0.518 
Cardiovascular complications    10 (24)      9 (23)   1.000 
Cumulated ambulation score 43.5 (24 - 56)  
[8 - 82] 
32 (19.2 - 48)  
[0 - 85] 
 0.137 
Length of hospital stay 
 log 
 days 
  
2.66 (0.45) 
14.2 (12.4 - 16.4) 
  
2.60 (0.54) 
13.4 (11.4 - 15.9) 
  
0.605 
Length of postoperative hospital stay 
 log 
 days 
  
2.56 (0.48) 
12.9 (11.1 - 15) 
  
2.48 (0.59) 
12 (9.9 - 14.4) 
  
0.527 
Discharge destination          0.349 
    Died     0      3 (8)   
    Nursing Home     1 (2)      2 (5)   
    Own Home    27 (66)     25 (64)   
    Rehab hospital    11 (27)      7 (18)   
    Residential Home     1 (2)     2 (5)  
    Warden controlled 
 accommodation 
    1 (2)     0  
Mortality at 30-days     0     4 (10)  0.112 
 
Data are reported as mean (sd), median (interquartile range) [range], or number (proportion). The mean (sd) for 
log transformed data are supplemented by the back-transformed mean (95% confidence interval). P values are 
from: two-side tests on the log-transformed data; chi-squared tests with continuity correction; and Mann-
Whitney-U tests on non-parametric data. 
 
 
 
 
 
